The COVID-19 inactivation protocol consists of heating 92° C-15min – 56° C-30min – Summer … no problem

0
431

Coronavirus disease 19 (COVID-19), classified as pandemic by WHO, is a severe acute respiratory syndrome (SARS) caused by the virus designated SARS-CoV-2 (1).

Since December 2019, measures to reduce person- to-person transmission of COVID-19 have been implemented to attempt control of the outbreak.

Tremendous efforts are done by an increasing number of scientific personnel working daily with the live virus and / or infectious samples, and thus heavily exposed to the risk of infection (2–4).

Accordingly, the WHO introduced laboratory guidelines to mitigate this risk for diagnosis and research activities (5). Nonetheless, laboratory workers processing clinical samples will continue to be exposed to infectious SARS-CoV-2 (6).

SARS-CoV-2 direct diagnosis is based on RNA detection by RT-qPCR (7).

The methods for nucleic acid (NA) extraction use buffers, which formulation intends to obtain high quality NAs. They are not primarily developed for inactivation. Automated NA extraction is generally performed outside of biosafety cabinets which demands that only non-infectious samples must be loaded.

To achieve this objective, a prior inactivation step under appropriate biosafety conditions is an absolute requirement. Previous studies have addressed the ability of lysis buffers added to the samples in initial step of NA extraction to act as inactivation agents of several pathogenic viruses  (including coronaviruses).

However, discrepant results observed with dissimilar protocols led to controversial conclusions (8–10). On another hand, the Center for Disease Control and Prevention (CDC) recommends using Triton X-100 and to heat the sample at 60°C for 1 hour for samples suspect of containing Viral Hemorrhagic Fever (VHF) agent.

This procedure has been adopted by many laboratories for handling samples that may contain Ebola virus. Others studies with SARS-CoV and MERS-CoV have established  that heat treatment can inactivate beta-coronaviruses (11,12).

Consequently, definitive validation to SARS-CoV-2 is still awaited. Soon or later during the COVID-19 pandemic, serological tests will be  used for diagnostics and for seroprevalence studies aiming at measuring the penetration of SARS-CoV-2 infection at population level. Detection of past infection will be pivotal for allowing immune persons to take back their professional activity.

Since SARS-CoV-2 was detected in blood during infection (13), samples will have to be inactivated prior to serological tests are performed (14). In this study, we have tested ten different protocols including three lysis buffers and six heat inactivation procedures on SARS- CoV-2 culture supernatant.  

Materials and methods Lysis buffers

Three lysis buffers produced by Qiagen (Hilden, Germany) were tested. Approximate composition of each buffer is provided by Qiagen. ATL (25-50% Guanidinium Thiocyanate [GITC] and 1-10% sodium dodecyl sulfate [SDS]), VXL (25-50% GITC, 2.5-10% Triton-X-100), and AVL (50-70% GITC).

Cell line

African green monkey kidney cells (Vero-E6; ATCC#CRL-1586) were grown at 37°C in 5% CO2 with 1% Penicillin/Streptomycin (PS; 5000U.mL-1 and 5000µg.mL-1; Life Technologies) and supplemented with  1% non-essential amino acids (Life Technologies) in Minimal Essential Medium (Life Technologies) with 5% FBS.

Viruses

The Human 2019 SARS-CoV-2 strain (Ref-SKU: 026V-03883) was isolated at Charite University (Berlin, Germany) and obtained from the European Virus Archive catalog (EVA-GLOBAL H2020 project) (https://www.european-virus-archive.com). Experiments were performed in BSL3 facilities.

SARS-CoV-2 titration

SARS-CoV-2 was first propagated and titrated on Vero-E6 cells. Virus stock was diluted to infect Vero-E6 cells at a MOI of 0.001; then cells were incubated at 37°C for 24-48 hours after which medium was changed and incubation was continued for 24 hr; then supernatant was collected, clarified by spinning at 1500 × g for 10 min, supplemented with 25mM HEPES (Sigma), and aliquoted. Aliquots were stored at – 80°C before titration.

Virus infectivity was measured using 50% tissue culture infectivity dose (TCID50); briefly, when cells were at 80% confluence, six replicates were infected with 150μL of tenfold serial dilutions of the virus sample, and incubated for 3-5 days at 37°C under 5% CO2. CPE was read using an inverted microscope, and infectivity was expressed as TCID50/mlbased on the Karber formula (15).

Inactivation assays with lysis buffer (Table 1)

The French norm NF EN 14476+A2 derived from the European standard EN 14885 was used (16). For simulating “dirty” conditions, 3 g/L BSA was added before inactivation (Table 1).

Each sample was incubated in duplicate with the lysis buffer at room temperature for 10 min; then lysis buffer was discarded via ultrafiltration with Vivaspin 500 columns (Sartorius, Göttingen, Germany) as described (17);column was washed with 500 µL PBS three times, and eluted in 20 µL of PBS; 0.1mL was inoculated onto Vero-E6 monolayer (70% confluence).

Controls consisted of uninoculated Vero-E6 cells, Vero-E6 cells inoculated with the tested lysis buffer (cytotoxicity), and Vero-E6 cells inoculated with SARS-CoV-2 only. Cells were incubated at 37 °C under 5% CO2 for 5 days. The read-out was the presence of CPE together with SARS-CoV-2 RNA detection through RT-qPCR at day 5; in the absence of CPE at day 5, 100 µL of supernatant was passaged with the same read-out 5 days later (day 10).

Heat inactivation assays (Table 2)

A 400-µL volume of SARS-CoV-2 supernatant (3.3×106 TCID /mL) was incubated in a pre-warmed  dry  heat block and immediately tested for measuring TCID50 and RNA copies. Virus titration was performed  in duplicate before and after heating to measure viral load reduction factor.

Integrity of SARS-CoV-2 RNA after heat inactivation

Heat inactivated samples were extracted using the Qiacube HT and the Cador pathogen extraction kit (both from Qiagen). Viral RNA was quantified by RT-qPCR (qRT-PCR EXPRESS One-Step Superscript™, ThermoFisher Scientific) (10min-50°C, 2 min-95°C, and 40 times 95°C-3 sec / 60°C-30 sec] using serial dilutions of a T7-generated synthetic RNA standard. Primers and probe target the N gene (Fw: GGCCGCAAATTGCACAAT; Rev : CCAATGCGCGACATTCC; Probe: FAM-CCCCCAGCGCTTCAGCGTTCT-BHQ1.The calculated limit of detection is 10 RNA copies per reaction.  

  Results

Inactivation assays with lysis buffer (Table 3)

VXL and ATL buffers were able to inactivate SARS-CoV-2 with viral loads as high as 106 TCID /ml. In contrast, AVL buffer (GITC 50-70%) either alone or in the presence of absolute ethanol or 1% Triton X- 100 resulted in a partial inactivation (50-75%). In addition, our results show that GITC alone (AVL buffer) or GITC mixed with absolute ethanol also cannot guarantee SARS-CoV-2 inactivation as previously described (10). Finally, there was no difference observed between clean and dirty (3 g/L BSA) conditions.

Heat inactivation assays (Table 4)

Only the 92°C-15min protocol was able to inactivate totally the virus (>6 Log10 decrease), whereas the two other protocols resulted in a clear drop of infectivity (5 Log10 reduction) but with remaining infectivity equal or lower than 10 TCID50/ml (Table 4). These results were consistent with  previous studies on SARS-CoV and MERS-CoV (11,12). There was no difference between clean or dirty conditions.  

Integrity of SARS-CoV-2 RNA after heat inactivation

The analysis of the Ct values (instead of the TCID50) showed that 56°C-30min and 60°C-60min did not affect significantly the number of detectable RNA copies (Δ Ct <1) (Table 4). In contrast, 92°C-15min resulted in a significant drop of the number of RNA copies (Δ Ct >5) (Table 4).

Discussion

Despite the previous emergence of SARS and MERS CoV, there are few studies on the inactivation protocols aiming at mitigating the risk of exposure for medical and laboratory personnel (18). 

Qiagen is a prominent actor in the field of nucleic acid purification. Most of other manufacturers of NA purification kits use similar lysis buffer as ATL, AVL and VXL. The ability of AVL to inactivate pathogenic viruses was debated (8–10) but there is no data for ATL and VXL.

A total of ten different protocols using AVL, ATL and VXL alone or in association with ethanol or Triton-X100 were studied on SARS-CoV-2 according to the French version of the European recommended procedure (NF EN 14476+A2) (16), as previously shown for other viruses such as Ebola virus or Foot and Mouth Disease virus (8,10,19,20). Our results are in line with data reported for Zaire Ebolavirus (10). They strongly suggest that ATL or VXL should be preferred to AVL. Our findings corroborate and expand recent results (21).

Considering that low SARS-CoV-2 viremia is observed in COVID-19 patients even at the acute stage of the disease (18), the 56°C-30min and 60°C-60min protocols commonly used before serology appears as sufficient for inactivating SARS-CoV-2 as recommended before serological assay for other enveloped RNA viruses (22).

Samples treated accordingly will also be amenable for viral RNA detection. In contrast, when processing respiratory samples commonly exhibiting much higher viral loads (23), only the 92°C-15min protocol showed total inactivation; however, whether this protocol is more efficient for inactivation than the two other, the drastic reduction of RNA copies that are detectable thereafter precludes its utilization for subsequent RT-qPCR detection of SARS-CoV-2. For the latter, inactivation using VXL, ATL or similar lysis buffer should be preferred.

Since clinical samples collected in COVID-19 suspect patients are commonly manipulated in BSL-2 laboratories, the results presented in this study should help to choose the best suited protocol for inactivation in order to prevent exposure of laboratory personnel in charge of direct and indirect detection of SARS-CoV-2 for diagnostic purpose.

  Funding

This study was partially funded (i) by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020-INFRAIA-2019 research and innovation programme, Project No 871029, (ii) “Advanced Nanosensing platforms for Point of care glovbal disgnostics and surveillance” (CONVAT) ,H2020, Project No101003544, (iii) PREPMedVet (Preparedness and Response in an Emergency contact to Pathogens of Medical and Veterinary importance) within the Agence Nationale de la Recherche Franco-German call on Civil security / Global security 2019 Edition, (iv) “Viral Hemorrhagic fever moden approaches for developing bedside rapid diagnostics, IMI2 Program, H2020, Project No823666. It was also supported by Inserm through the Reacting (REsearch and ACTion Targeing emerging infectious diseases) initiative.

Another study from Canada shows that temperature and latitude do not significantly affect COVID-19 … Indeed:

Temperature and latitude do not appear to be associated with the spread of coronavirus disease 2019 (COVID-19), according to a study of many countries published in CMAJ (Canadian Medical Association Journal), but school closures and other public health measures are having a positive effect.

“Our study provides important new evidence, using global data from the COVID-19 epidemic, that these public health interventions have reduced epidemic growth,” says Dr. Peter Jüni, Institute for Health Policy, Management and Evaluation, University of Toronto, and St. Michael’s Hospital, Toronto, Ontario.

The Canadian study looked at 144 geopolitical areas—states and provinces in Australia, the United States and Canada as well as various countries around the world—and a total of more than 375 600 confirmed COVID-19 cases. China, Italy, Iran and South Korea were excluded because the virus was either waning in the case of China or in full disease outbreak at the time of the analysis in others. To estimate epidemic growth, researchers compared the number of cases on March 27 with cases on March 20, 2020, and determined the influence of latitude, temperature, humidity, school closures, restrictions of mass gatherings and social distancing measured during the exposure period of March 7 to 13.

They found little or no association between latitude or temperature with epidemic growth of COVID-19 and a weak association between humidity and reduced transmission. The results—that hotter weather had no effect on the pandemic’s progression—surprised the authors.

“We had conducted a preliminary study that suggested both latitude and temperature could play a role,” says Dr. Jüni. “But when we repeated the study under much more rigorous conditions, we got the opposite result.”

The researchers did find that public health measures, including school closures, social distancing and restrictions of large gatherings, have been effective.

“Our results are of immediate relevance as many countries, and some Canadian provinces and territories, are considering easing or removing some of these public health interventions,” says Dr. Jüni.

“Summer is not going to make this go away,” says Prof. Dionne Gesink, a coauthor and epidemiologist at Dalla Lana School of Public Health. “It’s important people know that. On the other hand, the more public health interventions an area had in place, the bigger the impact on slowing the epidemic growth. These public health interventions are really important because they’re the only thing working right now to slow the epidemic.”

The authors note several study limitations, such as differences in testing practices, the inability to estimate actual rates of COVID-19 and compliance with social distancing.

When deciding how to lift restrictions, governments and public health authorities should carefully weigh the impact of these measures against potential economic and mental health harms and benefits.


Source More information: Canadian Medical Association Journal (2020). www.cmaj.ca/lookup/doi/10.1503/cmaj.200920

References

  1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Mar 10]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554776/
  2. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. 2016 Mar;92(3):235–50. 
  3. Xiao S, Li Y, Wong T, Hui DSC. Role of fomites in SARS transmission during the largest hospital outbreak in Hong Kong. Shaman J, editor. PLOS ONE. 2017 Jul 20;12(7):e0181558. 
  4. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA [Internet]. 2020 Mar 4 [cited 2020 Mar 10]; Available from: https://jamanetwork.com/journals/jama/fullarticle/2762692
  5. Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV) – Interim Guidance. World Health Organization (WHO); 2020. 
  6. Sagripanti J-L, Hülseweh B, Grote G, Voß L, Böhling K, Marschall H-J. Microbial Inactivation for Safe and Rapid Diagnostics of Infectious Samples. Appl Environ Microbiol. 2011 Oct 15;77(20):7289–95. 
  7. Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol. 2020 Mar 6;jmv.25749.  
  8. Blow JA, Dohm DJ, Negley DL, Mores CN. Virus inactivation by nucleic acid extraction reagents. J Virol Methods. 2004 Aug;119(2):195–8.  
  9. Ngo KA, Jones SA, Church TM, Fuschino ME, George KSt, Lamson DM, et al. Unreliable Inactivation of Viruses by Commonly Used Lysis Buffers. Appl Biosaf. 2017 Jun;22(2):56–9.  
  10. Smither SJ, Weller SA, Phelps A, Eastaugh L, Ngugi S, O’Brien LM, et al. Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type. Caliendo AM, editor. J Clin Microbiol. 2015 Oct;53(10):3148–54.
  11. Leclercq I, Batéjat C, Burguière AM, Manuguerra J-C. Heat inactivation of the Middle East respiratory syndrome coronavirus. Influenza Other Respir Viruses. 2014 Sep;8(5):585–6.  
  12. Darnell MER, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods. 2004 Oct;121(1):85–91.  
  13. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020 Feb;S1473309920301134. 
  14. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: Challenges and pitfalls. Virus Res. 2014 Dec;194:175–83. 
  15. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938 May;27(3):493–7. 
  16. French standard NF EN 14476+A2 October 2019 – Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area – Test method and requirements. AFNOR; 2019.
  17. Burton JE, Easterbrook L, Pitman J, Anderson D, Roddy S, Bailey D, et al. The effect of a non- denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples. J Virol Methods. 2017 Dec;250:34–40.  
  18. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev. 2020 Feb;S0887796320300146.  
  19. Wood BA, Mioulet V, Henry E, Gray A, Azhar M, Thapa B, et al. Inactivation of foot-and-mouth disease virus A/IRN/8/2015 with commercially available lysis buffers. J Virol Methods. 2020 Apr;278:113835. 
  20. Haddock E, Feldmann F, Feldmann H. Effective Chemical Inactivation of Ebola Virus. Emerg Infect Dis. 2016 Jul;22(7):1292–4. 
  21. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020 Mar 17;NEJMc2004973.
  22. Roehrig JT, Hombach J, Barrett ADT. Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. Viral Immunol. 2008 Jun;21(2):123–32.  
  23. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020 Mar 19;382(12):1177–9.  

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.